Caution advised after pioglitazone linked to bladder cancer
THE TGA has issued a safety advisory for pioglitazone (Actos) following research linking long-term use to an increased risk of bladder cancer.
A US study found patients with type 2 diabetes taking the medication for more than 24 months had 1.4 times the cancer risk of patients not taking it.
A preliminary assessment of data from a French trial also showed an increased risk of bladder cancer in patients taking the drug for more than 12 months, the TGA said.
“The TGA is advising health professionals and consumers that use of the diabetes medicine, pioglitazone, for more than a year may be associated